Taken together, these findings underscore the role of Dyrk1b as an attractive therapeutic target for the treatment of both NAFLD and T2D in the general population and for human DYRK1BR102C carriers. The gene discussed is DYRK1B; the disease is metabolic dysfunction-associated steatotic liver disease.